# A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D)

> **NCT03751007** · PHASE1,PHASE2 · COMPLETED · sponsor: **Precigen Actobio T1D, LLC** · enrollment: 45 (actual)

## Conditions studied

- Diabetes type1

## Interventions

- **BIOLOGICAL:** AG019 - Low Dose
- **DRUG:** Teplizumab
- **DRUG:** Placebo-AG019
- **DRUG:** Placebo-Teplizumab
- **BIOLOGICAL:** AG019 - High Dose
- **BIOLOGICAL:** AG019 - High Dose

## Key facts

- **NCT ID:** NCT03751007
- **Lead sponsor:** Precigen Actobio T1D, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-24
- **Primary completion:** 2021-10-13
- **Final completion:** 2021-10-13
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2023-02-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03751007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03751007, "A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D)". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT03751007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*